ReviewImmunotherapy2012
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.
Review in Immunotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Review
- Blood-brain barrier disruption: a culprit of cognitive decline?Fluids and barriers of the CNS · 2024Review
- Decision trees to evaluate the risk of developing multiple sclerosis.Frontiers in neuroinformatics · 2023Article
- BMSCs Promote Differentiation of Enteric Neural Precursor Cells to Maintain Neuronal Homeostasis in Mice With Enteric Nerve Injury.Cellular and molecular gastroenterology and hepatology · 2023Article
- Effect of stem cell treatment on functional recovery of spinocerebellar ataxia: systematic review and meta-analysis.Cerebellum & ataxias · 2021Review
- Human ES-derived MSCs correct TNF-α-mediated alterations in a blood-brain barrier model.Fluids and barriers of the CNS · 2019Article
- Mesenchymal stem cells in dogs with demyelinating leukoencephalitis as an experimental model of multiple sclerosis.Heliyon · 2019Article
- Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine.Regenerative medicine · 2019Review
- Transcriptional Profiling of Mesenchymal Stem Cells Identifies Distinct Neuroimmune Pathways Altered by CNS Disease.International journal of stem cells · 2018Article
- Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders.Pediatric research · 2018Review
- The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis.Stem cell research & therapy · 2017Article
- hMSCs suppress neutrophil-dominant airway inflammation in a murine model of asthma.Experimental & molecular medicine · 2017Article
- Gender difference in the neuroprotective effect of rat bone marrow mesenchymal cells against hypoxia-induced apoptosis of retinal ganglion cells.Neural regeneration research · 2016Article
- Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem cells during experimental autoimmune encephalomyelitis.Stem cell research & therapy · 2016Article
- Exosomes as a Nanodelivery System: a Key to the Future of Neuromedicine?Molecular neurobiology · 2016Review
- The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.Advanced biomedical research · 2016Review
- Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis.Stem cell reports · 2014Article
- Article
- Progress of mesenchymal stem cell therapy for neural and retinal diseases.World journal of stem cells · 2014Review
- Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway.Stem cells translational medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.